PROSTAID CalgaryCalgary's Prostate Cancer Support Group
Monthly Meeting: Tuesday, November 13th, 7:30PM at the Kerby Centre downtown. Dr. Jun Kawakami talks robotic assisted radical prostatectomy.

Public Funding of Therapies in Canada

Increase font size Decrease font size Reset font size

CUA 2018: Disparity in Public Funding of Therapies for Metastatic Castrate-Resistant Prostate Cancer Across Canadian Provinces

Halifax, Nova Scotia (UroToday.com) Treatment using abiraterone acetate, enzalutamide, cabazitaxel, and radium-223 (Ra-223) has been demonstrated to improve overall survival and quality of life for patients with metastatic castrate-resistant prostate cancer (mCRPC).  Despite their proven benefits, access to these therapies varies across Canada.

Using the Canadian Agency for Drugs and Technologies in Health (CADTH) pan-Canadian Oncology Drug Review (pCODR), provincial funding summaries, provincial cancer care guidelines and formularies, pharmaceutical manufacturers, and the GURC network of clinicians, provincial reimbursement policies were reviewed for approved mCRPC therapies where available.

As the results show, interprovincial disparities were observed in access to androgen receptor-axis-targeted (ARAT) therapies, radium-223, and cabazitaxel.  (Table 1, 2, 3).   

In conclusion, while all provinces have access to docetaxel and ARATs, access to various treatments, such as sandwiching sequential ARATs with docetaxel is funded only in some of the provinces. Ra-223 and cabazitaxel access vary considerably across Canada. These inequalities in access to life-prolonging therapies could potentially lead to disparities in survival and quality of life among mCRPC patients. 

Read more on the full study at URO Today.

 

Presented by: Dixon T.S. Woon, MD, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada 
Co-Authors: Thenappan Chandrasekar1, Lorne Aaron2, Naveen S. Basappa3, Kim N. Chi4, Henry J. Conter5, Brita Danielson3, Sebastien J. Hotte6, Shawn Malone7, Fred Saad8, Bobby Shayegan6, Laura Park-Wyllie9, Robert Hamilton1.
Author Information: 
1. Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
2. Service d-Urologie and Centre de la Prostate, Hôpital Charles LeMoyne, Longueuil, QC, Canada
3. Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada
4. BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada
5. William Osler Health System, University of Western Ontario, Brampton, ON, Canada
6. Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada
7. The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada
8. Centre Hospitalier de l’Université de Montréal, University of Montreal, Montreal, QC, Canada
9. Medical Affairs, Janssen Inc., Toronto, ON, Canada

Written By: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre, @GoldbergHanan at the 73rd Canadian Urological Association Annual Meeting - June 23 - 26, 2018 - Halifax, Nova Scotia

Donate Now to PROSTAID Calgary

Quick Links

• The Digital Examiner Journal
• Online Meeting Video Archive
• Who is PROSTAID Calgary?
• Contact Us

 
PROSTAID Calgary on Twitter PROSTAID Calgary on Facebook PROSTAID Calgary on YouTube Email PCCN Calgary Become a PROSTAID Calgary Member Today!
hits since 02.27.2008

Maybe you can live without a PSA test...but why take the chance?
PROSTAID Calgary is your first destination for prostate cancer support in Calgary, Alberta, Canada and across the world with information and support through our online videos, support meetings, prostate cancer news, and awareness initiatives.


All Rights Reserved . © 2005-2017 . PROSTAID Calgary & PCCN Calgary . Charitable Registration Number: BN 86926 1602 RR0001
Site Designed & Maintained by Rhettoric Media.